Babraham Bioscience Technologies expands number of companies on the Babraham Research Camp...


30-10-2003

Babraham Bioscience Technologies Ltd (BBTL), the wholly owned trading subsidiary of the Babraham Institute, has welcomed two new companies to its Bioincubator, and announced the selection of two fledgling biotechnology companies to join its BioConcepts programme.

The Babraham Bioincubator now houses 18 bioscience ventures. The two most recent tenants are CellFactors plc and Novexin Ltd. CellFactors is developing human cell-based therapies. It was founded in 1997, and opened its Cambridge office at the Bioincubator on 1st September 2003. Novexin Ltd is a new venture developing protein processing technology for industrial-scale production. Novexin moved into Bioincubator facilities on 1st October 2003.



Babraham BioConcepts, launched in April this year, is a technology-accelerator scheme that has been built on the success of BBTL's bioincubation activities.



BioConcepts assists in the establishment of new bioventures, supporting the translation of new biotechnologies into investment-ready opportunities.



The first two BioConcepts companies, CTM Biotech Ltd and Innova Biosciences Ltd, will benefit from the scheme's support facilities, which include office and laboratory accommodation, R&D support staff, access to management skills and business mentoring.



Dr David Hardman, Chief Executive of BBTL, said, 'I'm very pleased to welcome all four companies to the Babraham Research Campus.



'Our continuing success in attracting quality ventures to the Bioincubator and, more recently, to the technology accelerator means that we're now looking to the future of the Babraham Research Campus as a regional centre for the translation of science into valuable technology and products.'











Babraham Bioscience Technologies Ltd (BBTL) is the wholly-owned trading subsidiary of the Babraham Institute, a research charity sponsored by the Biotechnology and Biological Sciences Research Council and focused on fundamental, biomedical-related research.



BBTL manages all commercial activities on the Babraham Research Campus, including technology and knowledge transfer, provision of technical and administrative services, the Babraham Bioincubator and BioConcepts, and development of the Babraham Research Campus.



Babraham BioConcepts is part-funded by the East of England Development Agency as a Regional Enterprise Hub. For more information about BBTL, see www.babraham.com.



CTM Biotech Ltd has been set-up to help early-stage bioscience companies progress their pharmaceuticals from the laboratory to the clinic. The company aims to alleviate the bottleneck that exists between the clients' in-house, research-phase development and large-scale GMP production. CTM Biotech's services include project management, process development and non-GMP production.



Innova Biosciences Ltd is building a portfolio of innovative reagents and kits for high-throughput drug screening. The company is currently developing a universal kinase assay that will work with any combination of enzyme and substrate, and on multiple instrument platforms. The system will effectively eliminate assay development work for kinase targets and thus greatly accelerate kinase-based drug discovery projects.



CellFactors plc develops human cell lines and derivative products. Its lead technology, Skeletex, is a cell-derived material that makes bone grow. Key application areas for Skeletex are orthopaedics and dentistry. The company is pioneering cell-based therapies for neurological disorders with its Volante product for Parkinson's disease. CellFactors also has a range of cell lines, NeuCell, which reflect different parts of the brain, and are used in drug discovery and development. Underpinning its technology and products is a strong portfolio of patents.



Novexin Ltd is a biotechnology company seeking to commercialise and further develop its proprietary protein processing technology. The company is addressing the need for protein purification and refolding techniques that are robust, high-yielding and easy to scale-up for industrial production. Novexin is currently implementing its business plan that placed the company as a runner-up in the Cambridge University Entrepreneurs Competition, and has since won a DTI SMART award.



*******

Contact details:

Dr David J Hardman, Chief Executive Officer

Tel: +44 (0)1223 496205

Babraham Bioscience Technologies Ltd

Fax: +44 (0)1223 496020

Email: dj.hardman@babraham.co.uk

 

Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

Babraham Bioscience Technologies Limited